Lancet (London, England)

Once-weekly insulin efsitora alfa compared to once-daily insulin degludec in adults with type 2 diabetes using basal insulin

Updated

Abstract

A total of 986 participants were randomly allocated to receive either once-weekly insulin efsitora alfa or daily insulin degludec.

  • The least-squares mean change in HbA concentration at week 26 was -0.81 percentage points for efsitora and -0.72 percentage points for degludec, indicating non-inferiority.
  • Combined rates of level 2 or level 3 hypoglycaemia were similar for efsitora (0.84 events per patient-year) and degludec (0.74 events per patient-year).
  • Serious adverse events occurred in 16% of participants treated with efsitora and 11% of those treated with degludec, with the most frequent events being cardiovascular-related.
  • Nine deaths occurred during the trial, with no deaths related to the study treatment.
  • The trial demonstrated that efsitora is a well-tolerated option for adults with type 2 diabetes, potentially offering a reduced injection frequency compared to daily insulin.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of interests AP-T performs research and serves as an adviser on behalf of her employer for AbbVie, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, and Sanofi. RMB has received research support, has acted as a consultant, or has been on the scientific advisory board for Abbott Diabetes Care, Ascensia, CeQur, DexCom, Eli Lilly, Embecta, Hygieia, Insulet, Medscape, Medtronic, Novo Nordisk, Onduo, Roche DiabetesCare, Tandem Diabetes Care, Sanofi, United Healthcare, Vertex Pharmaceuticals, and Zealand Pharma. RMB's employer, the non-profit HealthPartners Institute, contracts for his services, and he receives no personal income from these activities. TSB receives or has received research support from Abbott Diabetes, Abbott Rapid Diagnostics, Biolinq, Dexcom, Lilly, Kowa, LifePlus, Medtronic, Novo Nordisk, Sanofi, and Senseonics and has received consulting honoraria from Abbott Diabetes, Abbott Rapid Diagnostics, CeQur, Lifescan, MannKind, Medtronic, Novo Nordisk, and Sanofi. HJ declares a consultant position for Sanofi US and Novo Nordisk; research support from Eli Lilly Japan, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, Sumitomo Dainippon Pharma, GlaxoSmithKline, Takeda Pharmaceuticals, Daiichi-Sankyo, Taisho Pharmaceutical, Astellas Pharma US, and AstraZeneca Pharmaceuticals; and speakers bureau participation from Sanofi US, Eli Lilly Japan, Takeda Pharmaceuticals, Astellas Pharma US, Mitsubishi Tanabe Pharma, Daiichi-Sankyo, Boehringer Ingelheim Pharmaceuticals, Kissei Pharmaceutical, Kowa Pharmaceuticals, Novartis Pharmaceuticals Corporation, AstraZeneca Pharmaceuticals, MSD, and Mochida Pharmaceutical. JRT has served as an advisory board and data safety monitoring board member to Medtronic; is President of the Arkansas Diabetes and Endocrinology Center and Medical Investigations; has received research support and speaking fees from Medtronic and Lilly; and has received research support from Novo Nordisk and Inversago Pharma, AstraZeneca, and Merck. LI, JM, KS, and RJT are employees and shareholders of Eli Lilly and Company.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free